Replimune (REPL) Cash from Financing Activities (2018 - 2026)

Replimune (REPL) posted Cash from Financing Activities of $55.7 million for Q1 2026, up 432.74% sequentially from $10.5 million in Q4 2025, and up 42279.55% YoY from N/an in Q1 2025.

Replimune (REPL) Cash from Financing Activities (2018 - 2026) Analysis & Trends

Replimune has reported Cash from Financing Activities for 9 years, with the latest figure at $55.7 million in Q1 2026.

  • Quarterly Cash from Financing Activities rose 42279.55% year-over-year to $55.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $66.3 million (down 73.73% YoY) and the FY2026 annual result came in at $66.3 million, down 73.73% from the prior year.
  • Cash from Financing Activities advanced to $55.7 million in Q1 2026 per REPL's latest filing, from $10.5 million in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $271.4 million in Q4 2022 and troughed at -$158000.0 in Q2 2025.
  • A 5-year average of $38.0 million and a median of $1.1 million in 2023 frame the typical range for Cash from Financing Activities.
  • The sharpest annual moves came in 2023 and 2026: Cash from Financing Activities plunged 121.45% in 2023, then surged 42279.55% in 2026.
  • Over 5 years, Cash from Financing Activities stood at $271.4 million in 2022, then sank by 94.52% to $14.9 million in 2023, then soared by 948.62% to $155.9 million in 2024, then tumbled by 93.3% to $10.5 million in 2025, then soared by 432.74% to $55.7 million in 2026.
  • According to Business Quant data, Cash from Financing Activities over the past three periods registered $55.7 million, $10.5 million, and $324000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -426.70 Mn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -1.22 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - 2.42 Bn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn -6.05 Mn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -207,909.22
7 Royalty Pharma 33.72 Bn 35.84 Bn - -273.15 Mn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 36.24 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 27.18 Mn
10 Replimune 1.24 Bn 1.24 Bn - 55.68 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 55.68 Mn
Mar 31, 2026 55.68 Mn
Dec 31, 2025 10.45 Mn
Dec 31, 2025 10.45 Mn
Sep 30, 2025 324,000.00
Sep 30, 2025 324,000.00
Jun 30, 2025 -158,000.00
Jun 30, 2025 -158,000.00
Mar 31, 2025 -132,000.00
Mar 31, 2025 -132,000.00
Dec 31, 2024 155.93 Mn
Dec 31, 2024 155.93 Mn
Sep 30, 2024 -39,000.00
Sep 30, 2024 -39,000.00
Jun 30, 2024 96.64 Mn
Jun 30, 2024 96.64 Mn
Mar 31, 2024 -130,000.00
Mar 31, 2024 -130,000.00
Dec 31, 2023 14.87 Mn
Dec 31, 2023 14.87 Mn